High-throughput molecular analysis from leftover of fine needle aspiration cytology of mammographically detected breast cancer

Translational Oncology

Volumn 5, Issue 3, 2012, Pages 180-189

  Annaratone, Laura ^a   Marchiò, Caterina ^a   Renzulli, Tommaso ^a   Castellano, Isabella ^a,b   Cantarella, Daniela ^a   Isella, Claudio ^a   Macrì, Luigia ^a,b   Mariscotti, Giovanna ^a,b   Balmativola, Davide ^a   Cantanna, Elisabetta ^a   Deambrogio, Cristina ^a   Pietribiasi, Francesca ^c   Arisio, Riccardo ^d   Schmitt, Fernando ^e   Medico, Enzo ^a   Sapino, Anna ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b Azienda Ospedaliera Universitaria San Giovanni Battista di Torino   (Italy)

^c S CROCE E CARLE HOSPITAL   (Italy)

^d Sant'Anna Hospital   (Italy)

^e University of Porto   (Portugal)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; RNA;

ARTICLE; ASPIRATION BIOPSY; ASPIRATION CYTOLOGY; BREAST CANCER; ECHOGRAPHY; GENE EXPRESSION PROFILING; GENETIC ANALYSIS; HISTOPATHOLOGY; IMMUNOHISTOCHEMISTRY; MAMMOGRAPHY; MICROARRAY ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

EID: 84862018887     PISSN: None     EISSN: 19365233     Source Type: Journal    
DOI: 10.1593/tlo.11343     Document Type: Article

References (10)

1. Gong Y, Yan K, Lin F, Anderson K, Sotiriou C, Andre F, Holmes FA, Valero V, Booser D, Pippen JE Jr, et al. (2007). Determination of oestrogen-receptor status and ERBB2 status of breast carcinoma: a gene-expression profiling study. Lancet Oncol 8, 203-211.
2. Lee JK, Coutant C, Kim YC, Qi Y, Theodorescu D, Symmans WF, Baggerly K, Rouzier R, and Pusztai L (2010). Prospective comparison of clinical and genomic multivariate predictors of response to neoadjuvant chemotherapy in breast cancer. Clin Cancer Res 16, 711-718.
3. Miller LD, Smeds J, George J, Vega VB, Vergara L, Ploner A, Pawitan Y, Hall P, Klaar S, Liu ET, et al. (2005). An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. Proc Natl Acad Sci USA 102, 13550-13555.
4. Sabatier R, Finetti P, Cervera N, Lambaudie E, Esterni B, Mamessier E, Tallet A, Chabannon C, Extra JM, Jacquemier J, et al. (2011). A gene expression signature identifies two prognostic subgroups of basal breast cancer. Breast Cancer Res Treat 126, 407-420.
5. Sotiriou C, Wirapati P, Loi S, Harris A, Fox S, Smeds J, Nordgren H, Farmer P, Praz V, Haibe-Kains B, et al. (2006). Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J Natl Cancer Inst 98, 262-272.
6. Wang Y, Klijn JG, Zhang Y, Sieuwerts AM, Look MP, Yang F, Talantov D, Timmermans M, Meijer-van Gelder ME, Yu J, et al. (2005). Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet 365, 671-679.
7. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, Booser D, Theriault RL, Buzdar AU, Dempsey PJ, et al. (2006). Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 24, 4236-4244.
8. Shi L, Reid LH, Jones WD, Shippy R, Warrington JA, Baker SC, Collins PJ, de Longueville F, Kawasaki ES, Lee KY, et al. (2006). The MicroArray Quality Control (MAQC) project shows inter-and intraplatform reproducibility of gene expression measurements. Nat Biotechnol 24, 1151-1161.
9. Dai H, van't Veer L, Lamb J, He YD, Mao M, Fine BM, Bernards R, van de Vijver M, Deutsch P, Sachs A, et al. (2005). A cell proliferation signature is a marker of extremely poor outcome in a subpopulation of breast cancer patients. Cancer Res 65, 4059-4066.
10. Mira A, Isella C, Renzulli T, Cantarella D, Martelli ML, and Medico E (2009). The GAB2 signaling scaffold promotes anchorage independence and drives a transcriptional response associated with metastatic progression of breast cancer. Oncogene 28, 4444-4455.